437 Optimised achilles VELOSTM process 2b manufacturing platform generates a significant dose boost of reactive CD8 and CD4 clonal neoantigen-reactive T cells for the treatment of solid cancer

Bibliographic Details
Main Authors:	Sergio A Quezada, Katy Newton, Monica Sassi, Sandro Gomez, Evi Rologi, Meghan Madigan, Joanne Tang, Sarah Thirkell, Samuel Jide Banwo, Temi Ogunleye, Sophie McKeeman, Claire Law, Unnaamalai Meyyappan, Eleni Kotsiou, Theres Oakes, Miha Kosmac, Luke Goodsell, Connor Carolan, Justin Ahern, Tim Hillyer, Bongi Ndlovu, Henrieta Fraser, Edward Samuel
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items